The trial aims to explore the therapy in healthy lean participants and those with obesity. Credit: Hunterframe/Shutterstock.
Antag Therapeutics has initiated a first-in-human, double-blind Phase Ia trial of the glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, AT-7687, intended for treating obesity.
AT-7687 is poised to offer an approach to obesity management by targeting GIPR. This is said to be a validated mechanism for enhancing weight loss, tolerability and efficacy of incretin-based therapies.
The trial will assess the therapy’s safety, pharmacokinetics and tolerability in both healthy lean participants and those with obesity.
Its top-line outcomes are anticipated in the fourth quarter of this year.
Upon completion of this trial, Antag plans to explore AT-7687 as a combo therapy in individuals who are already treated with a glucagon-like peptide-1 (GLP-1) receptor agonist. This subsequent trial is expected to begin this year-end.
Antag Therapeutics CEO Jörg Möller said: “While GLP-1-based therapies have transformed treatment options, many patients continue to face challenges with tolerability and long-term adherence.
“AT-7687 is uniquely designed to address these gaps, with remarkable potential both as a standalone therapy and as a powerful complement that may be flexibly combined with existing and future treatment options for more individualised therapy.
“By leveraging a novel mechanism of action, AT-7687 aims to deliver not only sustained and healthier weight loss but comprehensive long-term benefits across a range of indications.”
Antag noted that the current obesity treatments often fall short in helping individuals achieve their weight loss goals, and side effects like nausea and vomiting frequently lead to therapy discontinuation.
To overcome these limitations, the therapy claims to provide a “well-tolerated” and targeted solution that can be used as a single agent or in conjunction with other GLP-1 and amylin-based treatments.
The company also stated that AT-7687 might offer further cardiometabolic advantages, including better glycaemic control and enhanced body composition.
Email newsletter icon
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.